OBJECTIVE: To analyse the frequency and prognostic factors of radiographic progression in a series of Spanish patients with early rheumatoid arthritis (RA) after 1 yr of treatment with disease-modifying anti-rheumatic drugs (DMARDs). METHODS: Sixty patients (47 females, 13 males) with RA with a disease duration shorter than 2 yr [mean (s.d.) duration 9.5+/-6.6 months] were treated with the same therapeutic protocol using gold salts as the first DMARD and methotrexate as a second option, and were followed up for 1 yr. Radiographic progression in the hands and feet (total radiographic Larsen score and the erosion joint count) was used as the outcome variable. Clinical, laboratory, immunogenetic and radiographic data were obtained at study entry. Disease activity and response to therapy were measured at 6 and 12 months. RESULTS: Erosive disease was found in 21.7% of patients at baseline and in 38.3% after 1 yr. Although a substantial reduction in disease activity was observed during the 1 yr follow-up [disease activity score (DAS28) 5.8+/-0.8 at entry and 3.9+/-1.3 at 12 months, P < 0.001], the Larsen score rose from 1.9+/-3.3 to 5.6+/-9.8 after 1 yr. In 26.6% of patients, a raised erosion joint count was observed after 1 yr. Radiographic progression in the total joint radiographic damage (increase in Larsen score of >or=2) was observed in 36.6%. In the multivariate analysis, baseline pain [visual analogue scale (VAS)] and the presence of two copies of the shared epitope were associated with radiographic progression in the erosion joint count. Disease duration before study entry, VAS pain and Larsen score at baseline were significant predictors of radiographic progression in total damage (Larsen score). Baseline radiographic damage had the highest positive predictive value for progression. CONCLUSIONS: Radiographic progression was observed in up to 36.6% of patients with early RA after 1 yr of DMARD therapy in spite of a significant reduction in disease activity. Baseline factors, such as VAS pain, disease duration until DMARD therapy, damage score at baseline and the presence of two copies of the shared epitope, were associated with radiographic progression.
OBJECTIVE: To analyse the frequency and prognostic factors of radiographic progression in a series of Spanish patients with early rheumatoid arthritis (RA) after 1 yr of treatment with disease-modifying anti-rheumatic drugs (DMARDs). METHODS: Sixty patients (47 females, 13 males) with RA with a disease duration shorter than 2 yr [mean (s.d.) duration 9.5+/-6.6 months] were treated with the same therapeutic protocol using gold salts as the first DMARD and methotrexate as a second option, and were followed up for 1 yr. Radiographic progression in the hands and feet (total radiographic Larsen score and the erosion joint count) was used as the outcome variable. Clinical, laboratory, immunogenetic and radiographic data were obtained at study entry. Disease activity and response to therapy were measured at 6 and 12 months. RESULTS:Erosive disease was found in 21.7% of patients at baseline and in 38.3% after 1 yr. Although a substantial reduction in disease activity was observed during the 1 yr follow-up [disease activity score (DAS28) 5.8+/-0.8 at entry and 3.9+/-1.3 at 12 months, P < 0.001], the Larsen score rose from 1.9+/-3.3 to 5.6+/-9.8 after 1 yr. In 26.6% of patients, a raised erosion joint count was observed after 1 yr. Radiographic progression in the total joint radiographic damage (increase in Larsen score of >or=2) was observed in 36.6%. In the multivariate analysis, baseline pain [visual analogue scale (VAS)] and the presence of two copies of the shared epitope were associated with radiographic progression in the erosion joint count. Disease duration before study entry, VAS pain and Larsen score at baseline were significant predictors of radiographic progression in total damage (Larsen score). Baseline radiographic damage had the highest positive predictive value for progression. CONCLUSIONS: Radiographic progression was observed in up to 36.6% of patients with early RA after 1 yr of DMARD therapy in spite of a significant reduction in disease activity. Baseline factors, such as VAS pain, disease duration until DMARD therapy, damage score at baseline and the presence of two copies of the shared epitope, were associated with radiographic progression.
Authors: S Louis Bridges; Zenoria L Causey; Paula I Burgos; B Quynh N Huynh; Laura B Hughes; Maria I Danila; Amalia van Everdingen; Stephanie Ledbetter; Doyt L Conn; Ashutosh Tamhane; Andrew O Westfall; Beth L Jonas; Leigh F Callahan; Edwin A Smith; Richard Brasington; Larry W Moreland; Graciela S Alarcón; Désirée M van der Heijde Journal: Arthritis Care Res (Hoboken) Date: 2010-05 Impact factor: 4.794
Authors: G Salvador; R Sanmarti; A Garcia-Peiró; J R Rodríguez-Cros; J Muñoz-Gómez; J D Cañete Journal: Ann Rheum Dis Date: 2005-02 Impact factor: 19.103
Authors: Jeroen P Jansen; Maria-Cecilia Vieira; John D Bradley; Joseph C Cappelleri; Samuel H Zwillich; Gene V Wallenstein Journal: BMC Musculoskelet Disord Date: 2016-08-18 Impact factor: 2.362
Authors: Raimon Sanmartí; Eduard Graell; Maria L Perez; Guadalupe Ercilla; Odette Viñas; Jose A Gómez-Puerta; Jordi Gratacós; Alejandro Balsa; Maria J Gómara; Marta Larrosa; Juan D Cañete; Isabel Haro Journal: Arthritis Res Ther Date: 2009-09-02 Impact factor: 5.156
Authors: R Sanmartí; A Gómez-Centeno; G Ercilla; M Larrosa; O Viñas; I Vazquez; J A Gómez-Puerta; J Gratacós; G Salvador; J D Cañete Journal: Clin Rheumatol Date: 2006-11-16 Impact factor: 3.650